10/18/2024

Janusmed sex and gender

Janusmed sex and gender – Cefotaxime

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Cefotaxime

Cefotaxime

Class : A

Show all info

Print

Contact us

  1. Rocha JL, Tuon FF, Johnson JR. Sex, drugs, bugs, and age: rational selection of empirical therapy for outpatient urinary tract infection in an era of extensive antimicrobial resistance. Braz J Infect Dis. 2012;16:115-21.

  2. Ludwig E, Székely E, Csiba A, Graber H. Pharmacokinetics of cefotaxime and desacetylcefotaxime in elderly patients. Drugs. 1988;35 Suppl 2:51-6.

  3. Yost RL, Derendorf H. Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects. Ther Drug Monit. 1986;8:189-94.

  4. Guay DR, Matzke GR, Heim KL, Halstenson CE, Abraham PA, Keane WF. Influence of gender on the disposition of cefotaxime and desacetylcefotaxime. Ther Drug Monit. 1987;9:259-62.

  5. van der Willigen AH, Wagenvoort JH, Schalla WO, Knapp JS, Boot JM, Heeres-Weststrate PL et al. Randomized comparative study of 05 and 1 g of cefodizime (HR 221) versus 1 g of cefotaxime for acute uncomplicated urogenital gonorrhea. Antimicrob Agents Chemother. 1988;32:426-9.

  6. Handsfield HH, Holmes KK. Treatment of uncomplicated gonorrhea with cefotaxime. Sex Transm Dis. 1981;8:187-91.

  7. Judson FN, Eron LJ, Lutz FB, Rand KH, Tennican PO, Mogabgab WJ. Multicenter study of a single 500-mg dose of cefotaxime for treatment of uncomplicated gonorrhea. Sex Transm Dis. 1991;18:41-3.

  8. Concise. Stockholm: eHälsomyndigheten. 2015 [cited 2016-03-21.]

  1. Rocha JL, Tuon FF, Johnson JR. Sex, drugs, bugs, and age: rational selection of empirical therapy for outpatient urinary tract infection in an era of extensive antimicrobial resistance. Braz J Infect Dis. 2012;16:115-21.
  2. Ludwig E, Székely E, Csiba A, Graber H. Pharmacokinetics of cefotaxime and desacetylcefotaxime in elderly patients. Drugs. 1988;35 Suppl 2:51-6.
  3. Yost RL, Derendorf H. Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects. Ther Drug Monit. 1986;8:189-94.
  4. Guay DR, Matzke GR, Heim KL, Halstenson CE, Abraham PA, Keane WF. Influence of gender on the disposition of cefotaxime and desacetylcefotaxime. Ther Drug Monit. 1987;9:259-62.
  5. van der Willigen AH, Wagenvoort JH, Schalla WO, Knapp JS, Boot JM, Heeres-Weststrate PL et al. Randomized comparative study of 05 and 1 g of cefodizime (HR 221) versus 1 g of cefotaxime for acute uncomplicated urogenital gonorrhea. Antimicrob Agents Chemother. 1988;32:426-9.
  6. Handsfield HH, Holmes KK. Treatment of uncomplicated gonorrhea with cefotaxime. Sex Transm Dis. 1981;8:187-91.
  7. Judson FN, Eron LJ, Lutz FB, Rand KH, Tennican PO, Mogabgab WJ. Multicenter study of a single 500-mg dose of cefotaxime for treatment of uncomplicated gonorrhea. Sex Transm Dis. 1991;18:41-3.
  8. Concise. Stockholm: eHälsomyndigheten. 2015 [cited 2016-03-21.]